
|Videos|May 28, 2017
Dr. Ellis on Neoadjuvant Endocrine Therapy for Breast Cancer
Author(s)Matthew J. Ellis, MD, PhD
Matthew J. Ellis, MD, PhD, professor of Oncology and Medicine at Baylor College of Medicine, discusses neoadjuvant endocrine therapy for patients with breast cancer.
Advertisement
Matthew J. Ellis, MD, PhD, professor of Oncology and Medicine at Baylor College of Medicine, discusses neoadjuvant endocrine therapy for patients with breast cancer.
Patients often present with a larger breast mass, which puts the patient at high-risk of systemic recurrence, explains Ellis.
There was a subset of patients who did not see positive results with neoadjuvant chemotherapy, allowing neoadjuvant endocrine therapy to be investigated to attempt to shrink the tumor.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5




































